May 7, 2026 07:30AM
May 7, 2026 07:30AM
Mar 12, 2026 12:26PM
Mar 11, 2026 08:00AM
Mar 5, 2026 06:59AM
Mar 3, 2026 05:31PM
Jan 21, 2026 08:30AM Lexicon gets FDA clearance for pilavapadin phase 3 trials
Jan 21, 2026 08:30AM
Jan 20, 2026 07:00AM
Jan 20, 2026 06:59AM
Jan 12, 2026 07:30AM
Nov 6, 2025 07:30AM
Oct 14, 2025 08:01AM
Oct 14, 2025 08:00AM Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit
Sep 22, 2025 04:00PM
Sep 22, 2025 04:00PM
Sep 11, 2025 06:50AM
Sep 9, 2025 06:50AM
Sep 8, 2025 08:31AM
Sep 8, 2025 08:30AM
Sep 4, 2025 08:30AM Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025
Sep 3, 2025 08:30AM
Sep 2, 2025 08:33AM
Sep 2, 2025 08:30AM
Aug 6, 2025 12:06PM
Aug 6, 2025 07:30AM
Jul 18, 2025 08:00AM
May 13, 2025 04:00PM Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates
Mar 6, 2025 04:00PM
Mar 3, 2025 07:01AM
Mar 3, 2025 07:00AM
Dec 20, 2024 04:30PM
Nov 26, 2024 08:00AM
Nov 25, 2024 06:39AM
Nov 22, 2024 07:33AM Lexicon Pharma (LXRX) to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
Nov 22, 2024 07:32AM
Nov 12, 2024 04:05PM
Nov 5, 2024 04:05PM
Nov 4, 2024 08:00AM
Nov 1, 2024 07:22AM
Nov 1, 2024 06:40AM
Oct 31, 2024 06:54PM Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease
Oct 22, 2024 08:00AM
Oct 18, 2024 05:48AM
Oct 17, 2024 06:55AM
Oct 16, 2024 04:35PM
Oct 16, 2024 04:35PM
Oct 16, 2024 04:34PM
Sep 27, 2024 08:00AM Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress
Sep 3, 2024 08:00AM

322,246 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All